You just read:

YM BioSciences Reports Positive Interim Data Including Substantial Anemia Response from Phase I/II Trial of JAK1/JaK2 Inhibitor CYT387

News provided by

YM BioSciences Inc.

Dec 06, 2010, 11:15 ET